<SEC-DOCUMENT>0001193125-26-316771.txt : 20260727
<SEC-HEADER>0001193125-26-316771.hdr.sgml : 20260727
<ACCEPTANCE-DATETIME>20260727061002
ACCESSION NUMBER:		0001193125-26-316771
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		6
CONFORMED PERIOD OF REPORT:	20260727
FILED AS OF DATE:		20260727
DATE AS OF CHANGE:		20260727

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Sanofi
		CENTRAL INDEX KEY:			0001121404
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				133529324
		STATE OF INCORPORATION:			I0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-31368
		FILM NUMBER:		261202760

	BUSINESS ADDRESS:	
		STREET 1:		46 AVENUE DE LA GRANDE ARMEE
		CITY:			PARIS
		STATE:			I0
		ZIP:			75017
		BUSINESS PHONE:		33153774400

	MAIL ADDRESS:	
		STREET 1:		46 AVENUE DE LA GRANDE ARMEE
		CITY:			PARIS
		STATE:			I0
		ZIP:			75017

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SANOFI-AVENTIS
		DATE OF NAME CHANGE:	20040826

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SANOFI SYNTHELABO SA
		DATE OF NAME CHANGE:	20010104
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d150377d6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML><HEAD>
<TITLE>6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT STYLE="white-space:nowrap">6-K</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE <FONT STYLE="white-space:nowrap">13a-16</FONT> OR <FONT STYLE="white-space:nowrap">15d-16</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">For the month of July 2026 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">Commission File Number: <FONT STYLE="white-space:nowrap">001-31368</FONT> </P>
<P STYLE="margin-top:22pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>SANOFI </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">(Translation of
registrant&#8217;s name into English) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">46, avenue de la Grande Arm&eacute;e, 75017 Paris, FRANCE </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">(Address of principal executive offices) </P> <P STYLE="margin-top:36pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">Indicate
by check mark whether the registrant files or will file annual reports under cover Form <FONT STYLE="white-space:nowrap">20-F</FONT> or Form <FONT STYLE="white-space:nowrap">40-F.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">Form <FONT STYLE="white-space:nowrap">20-F</FONT> &#9746;&#8195;&#8195;&#8195;Form <FONT STYLE="white-space:nowrap">40-F</FONT> &#9744; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Verdana" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">In July 2026, Sanofi published the press releases attached hereto as Exhibit 99.1 and 99.2 which is
incorporated herein by reference. </P> <P STYLE="margin-top:28pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit Index </B></P> <P STYLE="font-size:42pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="89%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:9pt; font-family:Times New Roman; ">Exhibit&nbsp;No.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:9pt; font-family:Times New Roman; " ALIGN="center">Description</P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="44"></TD>
<TD HEIGHT="44" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" NOWRAP>Exhibit&nbsp;99.1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="d150377dex991.htm">Press Release dated July&nbsp;21, 2026: Sanofi evolves its Executive Committee to support its next strategic chapter </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" NOWRAP>Exhibit 99.2</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="d150377dex992.htm">Press Release dated July&nbsp;24, 2026: Sanofi announces decision not to submit amlitelimab in atopic dermatitis for global regulatory reviews </A></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Verdana" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">SIGNATURES </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:9pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top">Dated: July&nbsp;27, 2026</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">SANOFI</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt">


<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="89%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:9pt">By</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:9pt; font-family:Times New Roman" ALIGN="justify">/s/ Alexandra Roger</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name: Alexandra Roger</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title: Head of Legal Corporate&nbsp;&amp; Finance</TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Verdana" ALIGN="center">3 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d150377dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Arial" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Arial; font-size:14pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Arial; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Arial"><B>Press Release</B></P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">


<IMG SRC="g150377g0725022852296.jpg" ALT="LOGO">
</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:18pt; font-family:Georgia" ALIGN="justify"><FONT COLOR="#7a00e6"><I>Sanofi evolves its Executive Committee to support its next strategic chapter </I></FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Arial" ALIGN="justify"><B>Paris, July</B><B></B><B>&nbsp;21, 2026</B>. Sanofi today announced an evolution of its Executive Committee, bringing together a focused leadership
team across its businesses, scientific organization and key global functions as the company continues to deliver on its priorities and prepares its next strategic chapter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Arial" ALIGN="justify">Effective September&nbsp;1, 2026, Sanofi&#8217;s Executive Committee will comprise: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Arial; font-size:10pt">Fran&ccedil;ois Roger, Executive Vice President, Finance </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Arial; font-size:10pt">Paulo Fontoura, Executive Vice President, Head of Research&nbsp;&amp; Development </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Arial; font-size:10pt">Manuela Buxo, Executive Vice President, Specialty Care </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Arial; font-size:10pt">Thomas Triomphe, Executive Vice President, Vaccines </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Arial; font-size:10pt">Thomas Grenier, Executive Vice President, General Medicines </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Arial; font-size:10pt">Brendan O&#8217;Callaghan, Executive Vice President, Manufacturing&nbsp;&amp; Supply </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Arial; font-size:10pt">Jamie Haney, Executive Vice President, General Counsel </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Arial; font-size:10pt">V&eacute;ronique Jaillet, Executive Vice President, Chief People Officer, <I>ad interim </I> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Arial" ALIGN="justify">Emmanuel Frenehard, Head of Digital and Audrey Duval, Head of Corporate Affairs and President of Sanofi France, will continue to report directly to
Bel&eacute;n Garijo, Sanofi&#8217;s CEO. </P> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Arial" ALIGN="justify">Madeleine Roach, currently Head of Business Operations, will become President and Country Lead of Sanofi
Germany, Switzerland and Austria. Her current responsibilities, which focus on optimizing enterprise business services, will be integrated into the Finance function. Finance&#8217;s expanded remit will also include Global Partnering and Business
Development, helping drive a more integrated approach across Business Development and Mergers&nbsp;&amp; Acquisitions. </P> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Arial" ALIGN="justify">Thomas Triomphe will also
assume responsibility for China, alongside his role as Executive Vice President, Vaccines. </P> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Arial" ALIGN="justify">Olivier Charmeil, currently Executive Vice President,
General Medicines, will transition to Strategic Projects Advisor to the CEO. Throughout his career, Olivier has helped shape the company across a succession of leadership roles, with a deep and enduring commitment to its people, its business and the
patients it serves. Roy Papatheodorou, currently Executive Vice President, General Counsel, has decided to leave the organization to pursue external opportunities after over four years with the company, during which he has brought outstanding
leadership and contributions which went beyond his role as General Counsel. </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; margin-left:4%; margin-right:4%; font-size:10pt; font-family:Arial" ALIGN="justify"><FONT STYLE="font-family:Georgia"><I>&#8220;This Executive Committee brings together experienced professionals who will
work together to help shape our future direction, make disciplined choices, execute them with focus, and ensure we continue to deliver for our patients, our people and all our stakeholders. I would like to thank all those who have contributed to
Sanofi&#8217;s success and those who will continue to shape its future. I am deeply grateful for their leadership, commitment and dedication, and I wish everyone every success for the future,&#8221; </I></FONT><FONT STYLE="font-family:Arial">said
<B>Bel&eacute;n Garijo</B>, Chief Executive Officer of Sanofi. </FONT></P> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Arial" ALIGN="justify"><I>Biographies and pictures available on sanofi.com or upon request. </I></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:4.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #7f7f7f">&nbsp;</DIV>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Georgia"><FONT COLOR="#7a00e6"><I>About Sanofi </I></FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Arial" ALIGN="justify">Sanofi is an
R&amp;D driven, <FONT STYLE="white-space:nowrap">AI-powered</FONT> biopharma company committed to improving people&#8217;s lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines
that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more.&nbsp;Our team is guided by one purpose: we chase the miracles of science to improve people&#8217;s lives; this inspires us to
drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time. Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Georgia"><FONT COLOR="#7a00e6"><I>Media Relations </I></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Arial"><B>Sandrine Guendoul</B> | +33 6 25 09 14 25 | <FONT STYLE="font-family:Arial; font-size:8pt" COLOR="#7a00e6"><U>sandrine.guendoul@sanofi.com</U></FONT><FONT
STYLE="font-family:Arial"> </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Arial"><B>Evan Berland</B> | +1 215 432 0234 |
<FONT STYLE="font-family:Arial; font-size:8pt" COLOR="#7a00e6"><U>evan.berland@sanofi.com</U></FONT><FONT STYLE="font-family:Arial"> </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Arial"><B>L&eacute;o Le
Bourhis</B> | +33 6 75 06 43 81 | <FONT STYLE="font-family:Arial; font-size:8pt" COLOR="#7a00e6"><U>leo.lebourhis@sanofi.com</U></FONT><FONT STYLE="font-family:Arial"> </FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Arial"><B>L&eacute;a Ubaldi</B><B></B>&nbsp;| +33 6 30 19 66 46 |<FONT STYLE="font-family:Arial; font-size:8pt" COLOR="#7a00e6"><U>&nbsp;lea.ubaldi@sanofi.com</U></FONT><FONT
STYLE="font-family:Arial"> </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Arial"><B>Laura Romby</B>| +33 6 74 16 74 29 |
<FONT STYLE="font-family:Arial; font-size:8pt" COLOR="#7a00e6"><U>laura.romby@sanofi.com</U></FONT><FONT STYLE="font-family:Arial"> </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Arial"><B>Ekaterina Pesheva</B> |
+1 410 926 6780 | <FONT STYLE="font-family:Arial; font-size:8pt" COLOR="#7a00e6"><U>ekaterina.pescheva@sanofi.com</U></FONT><FONT STYLE="font-family:Arial"> </FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Arial"><B>Victor Rouault</B> | +1 617 356 4751 | <FONT STYLE="font-family:Arial; font-size:8pt" COLOR="#7a00e6"><U>victor.rouault@sanofi.com</U></FONT><FONT
STYLE="font-family:Arial"> </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Arial"><B>Timothy Gilbert</B> | +1 516 521 2929 |
<FONT STYLE="font-family:Arial; font-size:8pt" COLOR="#7a00e6"><U>timothy.gilbert@sanofi.com</U></FONT><FONT STYLE="font-family:Arial"> </FONT></P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:8pt; font-family:Georgia"><FONT
 COLOR="#7a00e6"><I>Investor Relations </I></FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Arial"><B>Thomas Kudsk Larsen</B> |+ 44 7545 513 693 |
<FONT STYLE="font-family:Arial; font-size:8pt" COLOR="#7a00e6"><U>thomas.larsen@sanofi.com</U></FONT><FONT STYLE="font-family:Arial"> </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Arial"><B>Aliz&eacute;
Kaisserian</B> | + 33 6 47 04 12 11 | <FONT STYLE="font-family:Arial; font-size:8pt" COLOR="#7a00e6"><U>alize.kaisserian@sanofi.com</U></FONT><FONT STYLE="font-family:Arial"> </FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Arial"><B>Keita Browne</B> | + 1 781 249 1766 |
<FONT STYLE="font-family:Arial; font-size:8pt" COLOR="#7a00e6"><U>keita.browne@sanofi.com</U></FONT><FONT STYLE="font-family:Arial"> </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Arial"><B>Nathalie Pham</B> | +
33 7 85 93 30 17 | <FONT STYLE="font-family:Arial; font-size:8pt" COLOR="#7a00e6"><U>nathalie.pham@sanofi.com</U></FONT><FONT STYLE="font-family:Arial"> </FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Arial"><B>Nina Goworek</B> | +1 908 569 7086 |
<FONT STYLE="font-family:Arial; font-size:8pt" COLOR="#7a00e6"><U>nina.goworek@sanofi.com</U></FONT><FONT STYLE="font-family:Arial"> </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Arial"><B>Thibaud
Ch&acirc;telet</B> | + 33 6 80 80 89 90 | <FONT STYLE="font-family:Arial; font-size:8pt" COLOR="#7a00e6"><U>thibaud.chatelet@sanofi.com</U></FONT><FONT STYLE="font-family:Arial"> </FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Arial"><B>Yun Li</B>&nbsp;| +33 6 84 00 90 72
|&nbsp;<FONT STYLE="font-family:Arial; font-size:8pt" COLOR="#7a00e6"><U>yun.li3@sanofi.com</U></FONT><FONT STYLE="font-family:Arial"> </FONT></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:7pt; font-family:Arial"><B><U>Sanofi
Forward-Looking Statements</U> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Arial" ALIGN="justify">This press release contains forward-looking statements within the meaning of applicable securities laws, including
the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding
plans, objectives, intentions, and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future events and economic performance. Words such as
&#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;intend,&#8221; &#8220;estimate,&#8221; &#8220;plan,&#8221; &#8220;can,&#8221; &#8220;contemplate,&#8221; &#8220;could,&#8221; &#8220;is designed to,&#8221;
&#8220;may,&#8221; &#8220;might,&#8221; &#8220;potential,&#8221; &#8220;objective,&#8221; &#8220;attempt,&#8221; &#8220;target,&#8221; &#8220;project,&#8221; &#8220;strategy,&#8221; &#8220;strive,&#8221; &#8220;desire,&#8221; &#8220;predict,&#8221;
&#8220;forecast,&#8221; &#8220;ambition,&#8221; &#8220;guideline,&#8221; &#8220;seek,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;goal,&#8221; or the negative of these, and similar expressions are intended to identify forward-looking
statements. Although Sanofi&#8217;s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and
uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking
information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as
the U.S Food and Drug Administration or the European Medicines Agency, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling
and other matters that could affect the availability or commercial potential of such product candidates; the fact that product candidates if approved may not be commercially successful; unexpected regulatory actions or delays, or government
regulation generally; authorities&#8217; decisions regarding whether and when to approve a product candidate; political pressure in the United States to mandate lower drug prices including &#8220;most favored nation&#8221; pricing for State Medicaid
programs; the future approval and commercial success of therapeutic alternatives; Sanofi&#8217;s ability to benefit from external growth opportunities, to complete related transactions and/or obtain regulatory clearances, including future clinical
data and analysis of existing clinical data relating to the product, including post marketing, unexpected safety, quality or manufacturing issues, competition in general; risks associated with intellectual property and any related pending or future
litigation and the ultimate outcome of such litigation;&nbsp;trends in exchange rates and prevailing interest rates, volatile economic and market conditions, cost containment initiatives and subsequent changes thereto, and the impact that global
crises may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. The risks and uncertainties also include the
uncertainties discussed or identified in the public filings with the SEC and the French Markets Authority (AMF) made by Sanofi, including those listed under &#8220;Risk Factors&#8221; and &#8220;Cautionary Statement Regarding Forward-Looking
Statements&#8221; in Sanofi&#8217;s annual report on Form <FONT STYLE="white-space:nowrap">20-F</FONT> for the year ended December&nbsp;31, 2025 or contained in our periodic reports on Form <FONT STYLE="white-space:nowrap">6-K.</FONT> Other than as
required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements. In light of these risks, uncertainties and assumptions, you should not place undue reliance on any
forward-looking statements contained herein. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Verdana; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt ; margin-bottom:0pt" ALIGN="justify">


<IMG SRC="g150377g13s50.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">2/2</TD></TR></TABLE>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>d150377dex992.htm
<DESCRIPTION>EX-99.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Verdana" ALIGN="right"><B>Exhibit 99.2 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Arial; font-size:14pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Arial; font-size:14pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Verdana" ALIGN="justify"><B>Press Release</B></P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">


<IMG SRC="g150377g0725023152932.jpg" ALT="LOGO">
</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:18pt; font-family:Georgia" ALIGN="justify"><FONT COLOR="#7a00e6"><I>Sanofi announces decision not to submit amlitelimab in atopic dermatitis for global
regulatory reviews </I></FONT></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Verdana" ALIGN="justify"><B>Paris, July</B><B></B><B>&nbsp;24, 2026.</B> Sanofi today announced the discontinuation of clinical development
of amlitelimab, an OX40-ligand monoclonal antibody, in <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">moderate-to-severe</FONT></FONT> atopic dermatitis (AD). This decision not to submit for global regulatory reviews was made as
part of an ongoing strategic assessment of the pipeline. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Verdana" ALIGN="justify">Sanofi has determined that the totality of efficacy and safety evidence generated to date
does not support further development of amlitelimab in AD. While the ESTUARY phase 3 long-term extension study (clinical study identifier: <FONT STYLE="font-family:Verdana; font-size:10pt" COLOR="#0463c1"><U>NCT06407934</U></FONT><FONT
STYLE="font-family:Verdana">) showed long-term maintenance of clinical response without relapse in patients aged 12 years and older with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">moderate-to-severe</FONT></FONT> AD and an
emerging safety profile that builds on previous data, amlitelimab would not represent a meaningful improvement to the standard of care for patients with AD. Additional results from the amlitelimab development program in AD, including from the
ESTUARY study, will be presented at a forthcoming medical meeting. </FONT></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Verdana" ALIGN="justify">Patients and their physicians need additional effective treatments due
to the heterogeneity of underlying immune mechanisms that contribute to AD, and Sanofi remains committed to pursuing advances in inflammatory skin conditions. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Verdana" ALIGN="justify">Sanofi is deeply grateful to the patients, caregivers, and investigators who supported the development of amlitelimab in AD, including in the ESTUARY
study. Sanofi will work closely with investigators, site teams, and regulatory authorities to ensure a wind-down of ongoing amlitelimab AD studies, with appropriate transition of care for all enrolled patients. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Verdana"><B>Financial considerations </B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:10pt; font-family:Verdana" ALIGN="justify">Sanofi is not amending its
full-year 2026 guidance as a result of this announcement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Verdana"><B>About amlitelimab </B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:10pt; font-family:Verdana" ALIGN="justify">Amlitelimab (SAR445229, KY1005) is a fully human, <FONT STYLE="white-space:nowrap">non-T</FONT> cell depleting monoclonal antibody that blocks the
OX40L, a key immune regulator. With its novel mechanism of action, amlitelimab selectively blocks OX40L signaling during the inflammatory prequel, the initiating phase of an overactive immune system, to potentially normalize <FONT
STYLE="white-space:nowrap">T-cell-mediated</FONT> inflammation without <FONT STYLE="white-space:nowrap">T-cell</FONT> depletion. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Verdana" ALIGN="justify">The phase 2 study
of amlitelimab in celiac disease is ongoing and expected to readout in the second half of 2026. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Georgia"><FONT COLOR="#7a00e6"><I>About Sanofi </I></FONT></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:10pt; font-family:Verdana" ALIGN="justify">Sanofi is an R&amp;D driven, <FONT STYLE="white-space:nowrap">AI-powered</FONT> biopharma company committed to improving people&#8217;s lives and
delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is
guided by one purpose: we chase the miracles of science to improve people&#8217;s lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare,
environmental, and societal challenges of our time. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Verdana">Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Georgia"><FONT COLOR="#7a00e6"><I>Sanofi Media Relations </I></FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Arial"><B>Sandrine Guendoul</B>
| +33 6 25 09 14 25 | <FONT STYLE="font-family:Arial; font-size:8pt" COLOR="#7a00e6"><U>sandrine.guendoul@sanofi.com</U></FONT><FONT STYLE="font-family:Arial"> </FONT></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8pt; font-family:Arial"><B>Evan Berland</B> | +1 215 432 0234 |
<FONT STYLE="font-family:Arial; font-size:8pt" COLOR="#7a00e6"><U>evan.berland@sanofi.com</U></FONT><FONT STYLE="font-family:Arial"> </FONT></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8pt; font-family:Arial"><B>L&eacute;o Le
Bourhis</B> | +33 6 75 06 43 81 | <FONT STYLE="font-family:Arial; font-size:8pt" COLOR="#7a00e6"><U>leo.lebourhis@sanofi.com</U></FONT><FONT STYLE="font-family:Arial"> </FONT></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8pt; font-family:Arial"><B>Victor Rouault</B> | +33 6 70 93 71 40 | <FONT STYLE="font-family:Arial; font-size:8pt" COLOR="#7a00e6"><U>victor.rouault@sanofi.com</U></FONT><FONT
STYLE="font-family:Arial"> </FONT></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8pt; font-family:Arial"><B>Timothy Gilbert</B> | +1 516 521 2929 |
<FONT STYLE="font-family:Arial; font-size:8pt" COLOR="#7a00e6"><U>timothy.gilbert@sanofi.com</U></FONT><FONT STYLE="font-family:Arial"> </FONT></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8pt; font-family:Arial"><B>L&eacute;a Ubaldi
</B>| +33 6 30 19 66 46 | <FONT STYLE="font-family:Arial; font-size:8pt" COLOR="#7a00e6"><U>lea.ubaldi@sanofi.com</U></FONT><FONT STYLE="font-family:Arial"> </FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Arial"><B>Ekaterina Pesheva </B>| +1 410 926 6780 | <FONT STYLE="font-family:Arial; font-size:8pt" COLOR="#7a00e6"><U>ekaterina.pesheva@sanofi.com</U></FONT><FONT
STYLE="font-family:Arial"> </FONT></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Georgia"><FONT COLOR="#7a00e6"><I>Sanofi Investor Relations </I></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Arial"><B>Thomas Kudsk Larsen</B> |+44 7545 513 693 | <FONT STYLE="font-family:Arial; font-size:8pt" COLOR="#7a00e6"><U>thomas.larsen@sanofi.com</U></FONT><FONT
STYLE="font-family:Arial"> </FONT></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8pt; font-family:Arial"><B>Aliz&eacute; Kaisserian</B> | +33 6 47 04 12 11 |
<FONT STYLE="font-family:Arial; font-size:8pt" COLOR="#7a00e6"><U>alize.kaisserian@sanofi.com</U></FONT><FONT STYLE="font-family:Arial"> </FONT></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8pt; font-family:Arial"><B>Keita Browne</B> |
+1 781 249 1766 | <FONT STYLE="font-family:Arial; font-size:8pt" COLOR="#7a00e6"><U>keita.browne@sanofi.com</U></FONT><FONT STYLE="font-family:Arial"> </FONT></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8pt; font-family:Arial"><B>Nathalie Pham</B> | +33 7 85 93 30 17 | <FONT STYLE="font-family:Arial; font-size:8pt" COLOR="#7a00e6"><U>nathalie.pham@sanofi.com</U></FONT><FONT
STYLE="font-family:Arial"> <B> </B></FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Arial"><B>Nina Goworek </B>| +1 908 569 7086 |
<FONT STYLE="font-family:Arial; font-size:8pt" COLOR="#7a00e6"><U>nina.goworek@sanofi.com</U></FONT><FONT STYLE="font-family:Arial"> </FONT></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8pt; font-family:Arial"><B>Thibaud
Ch&acirc;telet</B> | +33 6 80 80 89 90 | <FONT STYLE="font-family:Arial; font-size:8pt" COLOR="#7a00e6"><U>thibaud.chatelet@sanofi.com</U></FONT><FONT STYLE="font-family:Arial"> </FONT></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8pt; font-family:Arial"><B>Yun Li</B> | +33 6 84 00 90 72 | <FONT STYLE="font-family:Arial; font-size:8pt" COLOR="#7a00e6"><U>yun.li3@sanofi.com</U></FONT><FONT STYLE="font-family:Arial">
</FONT></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #7f7f7f">&nbsp;</DIV>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:8pt; font-family:Arial"><B><U>Sanofi Forward-Looking Statements</U> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:Arial" ALIGN="justify">This press release
contains forward-looking statements within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995, as amended. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:Arial" ALIGN="justify">Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying
assumptions, statements regarding plans, objectives, intentions, and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future events and economic
performance. Words such as &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;intend,&#8221; &#8220;estimate,&#8221; &#8220;plan,&#8221; &#8220;can,&#8221; &#8220;contemplate,&#8221; &#8220;could,&#8221; &#8220;is designed
to,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;potential,&#8221; &#8220;objective,&#8221; &#8220;attempt,&#8221; &#8220;target,&#8221; &#8220;project,&#8221; &#8220;strategy,&#8221; &#8220;strive,&#8221; &#8220;desire,&#8221;
&#8220;predict,&#8221; &#8220;forecast,&#8221; &#8220;ambition,&#8221; &#8220;guideline,&#8221; &#8220;seek,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;goal,&#8221; or the negative of these, and similar expressions are intended to
identify forward-looking statements. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:Arial" ALIGN="justify">Although Sanofi&#8217;s management believes that the expectations reflected in such forward-looking statements
are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual
results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and
development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the U.S Food and Drug Administration or the European Medicines Agency, regarding whether and when to approve any drug, device or
biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates; the fact that product
candidates if approved may not be commercially successful; unexpected regulatory actions or delays, or government regulation generally; authorities&#8217; decisions regarding whether and when to approve a product candidate; political pressure in the
United States to mandate lower drug prices including &#8220;most favored nation&#8221; pricing for State Medicaid programs; the future approval and commercial success of therapeutic alternatives; Sanofi&#8217;s ability to benefit from external
growth opportunities, to complete related transactions and/or obtain regulatory clearances, including future clinical data and analysis of existing clinical data relating to the product, including post marketing, unexpected safety, quality or
manufacturing issues, competition in general; risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation; trends in exchange rates and prevailing interest rates, volatile
economic and market conditions, cost containment initiatives and subsequent changes thereto, and the impact that global crises may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of
them, as well as on our employees and on the global economy as a whole. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the French Markets Authority (AMF) made by Sanofi,
including those listed under &#8220;Risk Factors&#8221; and &#8220;Cautionary Statement Regarding ForwardLooking Statements&#8221; in Sanofi&#8217;s annual report on Form <FONT STYLE="white-space:nowrap">20-F</FONT> for the year ended
December&nbsp;31, 2025 or contained in our periodic reports on Form <FONT STYLE="white-space:nowrap">6-K.</FONT> Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information
or statements. In light of these risks, uncertainties and assumptions, you should not place undue reliance on any forward-looking statements contained herein. </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g150377g0725022852296.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g150377g0725022852296.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  I )(# 2(  A$! Q$!_\0
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J _PW_9%^(F@_#OPMIE[86L5Y9:5:VT\?VE3MD2%589'H0:*^^** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g150377g0725023152932.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g150377g0725023152932.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  G )(# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z*^0?VU
M/^"BOA;]E"\3PU8Z<?%7CJ:$3_V<LOE06:-G:\SX/)QD(.2.3@$9^"+K_@LS
M\<9;YI8=)\(06V<B Z?,V!Z;O.S0!^VM%?E_\"?^"T%KKFJV.D_$SP9_9QN)
M%B.K: [2(I)P"8&RV/\ =8GVK],KG7+&QT635KNYCM-.C@^TR7%PWEI''MW%
MF)Q@ >M %ZBOS)_:#_X+,Z5X;UBZT?X4^&X?$0@8H=<U=W2W<@X/EQ+AF7_:
M+#/I7BNC_P#!:CXN6UZCZEX4\*7UKGYHH89X6(]F\UL?E0!^T%%?'7['/_!2
M+PS^U;XI/A*7PW>>%_% MWN$A,PN+>94&6VN I! YP1^-=M^V-^VUX;_ &/M
M(TF35=%OO$&JZMO^QV5JZQ*0O5GD(.T<CH": /H^BOQM\5?\%KOB7>WKGP]X
M*\-Z5:9^5+TS74F/=@Z#]*VOAI_P6P\66NK0Q^// ^DZAIC,!)-HCR6\T8[D
M*[.&^F1]: /UXHKB_@_\7O#/QS\ Z;XP\)7WV[1[Y,J67:\;#[R.IY5@>"*X
M;]J+]K?P/^REX235?%%P]UJ5UE;#1K0@W%TP_P#05]6/'UH ]MHK\:O%/_!:
MOXGWFKRR>'_!WAK3-,W?NX+Y9KF7'^TX=!GZ+7NW[-'_  6%T'Q_KUEX>^)^
MA0^$KRZ=88M9L9&>S+DX D1@6C&?XLD>N* /T?K\COV^_P#@IAXUL_B5JWP\
M^%&J_P!@:;H\YM+S6K5 UU=3KPZ1L<[$5LC(&21G.*_6N.ZCN;1;B"1)8G3>
MDB'*L",@@]Q7\T-[XQ;PA\?;CQ1/90ZP^FZ^U^UG=?ZNX*3E]K^QQS0!]A_L
MXV?[9>L_&#X?ZAK5]\28/"NHZK;27MWJ$DQMVM=X:3S%?("E 1\P'6OH[]OG
MXO\ Q5\%_&*UTW1=7U;0/#J6<,MDVFNT2W+D?.S,OWF#97!Z #CGGD_@!_P5
MR\4_%WXS>#?!-YX!TC3[/6]0CL7N;>[E+Q!N-R@C!QQQ7:_MQ?\ !2#5OV:_
MC4W@6S\!Z1XBM[:RM[W[7J4S;O,D!/RJ!@8&.>M?1Y!FM+)L:L56H*JK-6?G
MU5T]?ELV>A@<3'"5O:3@I*VS/5?!7Q2^.=[X-T&XGT-KF::PMY'FGM=LDC&-
M2688&"3R1@452\$?MY7WBCP7H&LS^$[>"?4=/M[R2*.[8JC21JY RO0$T5O/
M.L/.;DL'35WV9;QD&V_8Q/R)_;(N;NX_:]^*#Z_YSNOB2Y65<_,(1*0H7/;8
M%QVQBOU2_9^\*?L3?%KP)I.E>&M$\%W5P]ND3V.M+''JQ?;@[_,(D9\_Q*2/
M0UH?MF?L*_"_]J3Q>+FV\467A#XI& )F*5'-XH!V":#<&) _C7G YR *_.OX
MN_\ !+KX[_""VFU.TTFW\7Z?;DO]H\-S-+,JCG=Y157_ "!KYB4)0MS*U]3S
M6FMT?HII_P#P2C^$GA_XT>'/'?A^XO\ 3-/TJ[%[)X=D(N+:>13N3#N=R*"
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=3K2&ZMM)M(9H_MD;;'6% PR"0<$'H<4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g150377g13s50.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g150377g13s50.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  ? %@# 1$  A$! Q$!_\0
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MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z "@ H
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M^!W"YL=*@BD!]0RJ"* -WQ#X*\/^+FM3KFAZ=K)M6WP&_M(Y_*;U7<#M/TH
MLZ[X<TGQ1IKZ=K.F6>K:>Y!:UO8%FB8@Y&58$<4 3Z?I5EI&G0V%C:06=C"G
MEQVT$82-%_NA0, >U ')V?P1^'FG>(/[=M? OARVUK=O_M"+2H%GW?WMX7.?
M?- '3:YX?TOQ/ILFG:QIUIJMA*07M;V%9HGP<C*L"#@T 2Z;I%CH^FPZ?86=
MO96$*>7':V\2I$B^@4# 'M0!RFA?#CPQ\--=\1^*-*MUT6"_L+>*\LK.)([1
8!;/<R>>L:(#YK_:6#MD[A%$ !MY /__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
